USFDA1 Oct 2025, 06:01 pm
Ambalal Sarabhai Enterprises' Subsidiary Gets USFDA Approval for 6th Consecutive Time
AI Summary
Ambalal Sarabhai Enterprises Ltd. has announced that Synbiotics Limited, its wholly-owned subsidiary, has successfully received approval from The United States Food and Drug Administration (USFDA) for the 6th consecutive time for Good Manufacturing Practice (GMP) compliance. The inspection was conducted in accordance with the compliance program — Active Pharmaceutical Ingredient (API) Process Inspection in April 2025. This repeated approval highlights the company's commitment to maintaining high standards in the production of fermentation-based Active Pharmaceutical Ingredients and its Amphotericin B manufacturing facility.
Key Highlights
- Synbiotics Limited, a subsidiary of Ambalal Sarabhai Enterprises Ltd, received USFDA approval for the 6th consecutive time for GMP compliance.
- The approval was given after an inspection conducted in April 2025, in accordance with the API Process Inspection compliance program.
- The company is one of the few Amphotericin B manufacturing facilities in the world.
- The repeated approval underscores the company's commitment to maintaining high standards in the production of fermentation-based Active Pharmaceutical Ingredients.
- This is a significant achievement for Ambalal Sarabhai Enterprises Ltd, demonstrating their commitment to quality and regulatory compliance.